Extracorporeal Life Support in Patients with Hematologic Malignancies: A Single Center Experience.
10.5090/kjtcs.2016.49.4.280
- Author:
Kuk Bin CHOI
1
;
Hwan Wook KIM
;
Keon Hyon JO
;
Do Yeon KIM
;
Hang Jun CHOI
;
Seok Beom HONG
Author Information
1. Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Korea. kimhwanwook@gmail.com
- Publication Type:Original Article
- Keywords:
Extracorporeal membrane oxygenation;
Acute respiratory distress syndrome (ARDS);
Hematology
- MeSH:
Extracorporeal Membrane Oxygenation;
Hematologic Neoplasms*;
Hematology;
Humans;
Multivariate Analysis;
Platelet Transfusion;
Prognosis;
Respiratory Insufficiency;
Stem Cell Transplantation;
Survival Rate
- From:The Korean Journal of Thoracic and Cardiovascular Surgery
2016;49(4):280-286
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Extracorporeal life support (ECLS) in patients with hematologic malignancies is considered to have a poor prognosis. However, to date, there is only one case series reported in the literature. In this study, we compared the in-hospital survival of ECLS in patients with and without hematologic malignancies. METHODS: We reviewed a total of 66 patients who underwent ECLS for treatment of acute respiratory failure from January 2012 to December 2014. Of these patients, 22 (32%) were diagnosed with hematologic malignancies, and 13 (59%) underwent stem cell transplantation before ECLS. RESULTS: The in-hospital survival rate of patients with hematologic malignancies was 5% (1/22), while that of patients without malignancies was 26% (12/46). The number of platelet transfusions was significantly higher in patients with hematologic malignancies (9.69±7.55 vs. 3.12±3.42 units/day). Multivariate analysis showed that the presence of hematologic malignancies was a significant negative predictor of survival to discharge (odds ratio, 0.07; 95% confidence interval, 0.01–0.79); p=0.031). CONCLUSION: ECLS in patients with hematologic malignancies had a lower in-hospital survival rate, compared to patients without hematologic malignancies.
